Safety of adalimumab in Crohn's disease during pregnancy: case report and review of the literature.
Jürgens
Matthias
M
Brand
Stephan
S
Filik
Levent
L
Hübener
Christoph
C
Hasbargen
Uwe
U
Beigel
Florian
F
Tillack
Cornelia
C
Göke
Burkhard
B
Ochsenkühn
Thomas
T
Seiderer
Julia
J
D000068879:Adalimumab; D000328:Adult; D000893:Anti-Inflammatory Agents / Q000009:adverse effects / Q000627:therapeutic use*; D000911:Antibodies, Monoclonal / Q000009:adverse effects / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D003424:Crohn Disease / Q000188:drug therapy* / Q000473:pathology; D005260:Female; D006801:Humans; D011247:Pregnancy; D011248:Pregnancy Complications; D014409:Tumor Necrosis Factor-alpha / Q000276:immunology*
D000893:Anti-Inflammatory Agents; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D014409:Tumor Necrosis Factor-alpha; D000068879:Adalimumab